Previous Article | Next Article 
Infection and Immunity, May 2000, p. 2431-2434, Vol. 68, No. 5
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Are B Lymphocytes of Importance in Severe
Staphylococcus aureus Infections?
Inger
Gjertsson,1,*
Olof
Hörnquist
Hultgren,1
Martin
Stenson,1
Rikard
Holmdahl,2 and
Andrzej
Tarkowski1
Department of Rheumatology, University of
Göteborg, Göteborg,1 and
Section for Medical Inflammation Research, CMB, University of
Lund, Lund,2 Sweden
Received 12 October 1999/Returned for modification 6 December
1999/Accepted 25 January 2000
 |
ABSTRACT |
To investigate the role of B cells in experimental,
superantigen-mediated Staphylococcus aureus arthritis and
sepsis, we used gene-targeted B-cell-deficient mice. The mice were
inoculated intravenously with a toxic shock syndrome toxin 1 (TSST-1)-producing S. aureus strain. The B-cell-deficient
and thus agamma-globulinemic mice showed striking similarities to the
wild-type control animals with respect to the development of arthritis,
the mortality rate, and the rate of bacterial clearance. Surprisingly,
we found that the levels of gamma interferon in serum were
significantly lower (P < 0.0001) in B-cell-deficient
mice than in the controls, possibly due to impaired superantigen
presentation and a diminished expression of costimulatory molecules. In
contrast, the levels of interleukin-4 (IL-4), IL-6, and IL-10 in serum
were equal in both groups. Our findings demonstrate that neither mature
B cells nor their products significantly contribute to the course of
S. aureus-induced septic arthritis.
 |
INTRODUCTION |
We have previously described a
murine model of hematogenously induced Staphylococcus aureus
arthritis and sepsis (7, 8). Using this model, approximately
80 to 90% of mice inoculated with S. aureus LS-1 develop
clinical arthritis. Immunohistochemical analysis of arthritic joints
demonstrated the presence of phagocytes and T cells, predominantly of
the CD4 phenotype (4). The infected mice displayed increased
levels of inflammatory cytokines, such as tumor necrosis factor and
interleukin-6 (IL-6) in serum (7). We have also shown that
toxic shock syndrome toxin 1 (TSST-1), a superantigen produced by
S. aureus LS-1, contributes to the arthritogenicity of
S. aureus (3, 5). A series of studies using this
model suggested that S. aureus arthritis is a
T-cell-dependent and superantigen mediated disease.
As to the role of B cells in S. aureus arthritis, we have
found that a striking feature in this model is the occurrence of polyclonal B-cell activation with highly increased levels of
immunoglobulins and autoantibodies in serum (7). Using
X-linked immunodeficiency (xid) mice to investigate the contribution of
the B1 subset of B cells to the development of septic arthritis, it was
found that this defect provided resistance (21). Since the
B1 subset is considered to be of importance in the production of
autoantibodies, it was hypothesized that the outcome of the experiment
might have been due to this fact.
The aim of this study was to investigate if mature B cells,
irrespective of their B1 or B2 phenotype, and their products including cytokines, autoantibodies, and antibodies to bacterial constituents would affect the outcome of S. aureus-induced arthritis and
sepsis. We report here that a complete absence of mature B cells has no impact on the outcome of these very severe and life-threatening conditions.
 |
MATERIALS AND METHODS |
Mice.
Gene-targeted B-cell-deficient µMT mice
(C57BL/6 × 129) (11) were backcrossed to B10.Q
(H-2q) mice for eight generations and then
further intercrossed for two generations to provide homozygous B10.Q
mice lacking functional B cells (µMT-BQ) (19). All the
offspring were investigated for the presence of serum immunoglobulins
(IgM and IgG). The mice were maintained in the animal facility of the
Department of Rheumatology, University of Göteborg. Up to 11 mice
were kept in each cage, and they were fed standard laboratory chow and
water ad libitum. Three independent experiments were performed when the
mice were 6, 20, and 24 weeks old.
Bacteria and inoculation.
S. aureus LS-1 used in the
experiments has been previously described (8). One of the
characteristics of this strain is that it produces large amounts of
TSST-1, an exotoxin with superantigenic properties (7). The
bacteria were cultured on blood agar for 24 h and then reincubated
on blood agar for another 24 h. They were kept frozen at
20°C
in phosphate-buffered saline (PBS) (0.13 M sodium chloride, 10 mM
sodium phosphate [pH 7.4]) containing 5% bovine serum albumin and
10% dimethyl sulfoxide (C2H6OS) until use.
Before the experiments were started, the bacterial solution was thawed,
washed in PBS once, and diluted in PBS to achieve the desired
concentration of bacteria. Mice were inoculated in one of the tail
veins with 0.2 ml of bacterial solution. One group received a low
(suboptimal) arthritogenic dose (1 × 107/mouse), the
second group received a moderate (optimal) arthritogenic dose (4 × 107 CFU/mouse), and the third group was injected with an
high, septic dose (1 × 109 CFU/mouse) of the
bacteria. Viable counts in the leftover solution were determined to
ascertain the number of bacteria injected.
Clinical evaluation of arthritis.
All the mice were followed
up individually, and arthritis was evaluated. The limbs were evaluated
by a blinded observer on days 0, 2 to 4, 7, and 10 to 11 after
bacterial inoculation. The joints inspected included finger/toe and
ankle/wrist joints. Arthritis was defined as visible erythema and/or
swelling of a joint. To evaluate the intensity of arthritis, a clinical
scoring (arthritis index) was carried out using a system where
macroscopic inspection yielded a score of 0 to 3 points for each limb
(0, neither swelling nor erythema; 1, mild swelling and/or erythema; 2, moderate swelling and erythema; 3, marked swelling and erythema)
(2). The total score was calculated by adding all the scores
for each animal tested. The overall condition was evaluated by
assessment of weight and general appearance.
Histopathologic examination.
Histopathologic examination of
the joints was performed after routine fixation, decalcification, and
paraffin embedding. Tissue sections from fore- and hindpaws from the
experiment with the lowest (1 × 107) bacterial dose
were cut and stained with hematoxylin-eosin. All the slides were coded
and evaluated by two blinded observers. The specimens were evaluated
with regard to synovial hypertrophy, pannus formation, and
cartilage/subchondral-bone destruction. The degree of synovitis and
destruction yielded each a score from 0 to 3 in every joint, i.e.,
finger/toes, wrists/ankles, elbows, and knees.
Bacteriological examination.
Bacterial growth in blood was
examined after 18 h and 3 days in the "septic-dose"
experiment. The bacterial content in both kidneys and the liver was
examined at the time of sacrifice. The different organs were
aseptically removed, ground, and diluted with 10 ml of PBS. Appropriate
dilutions were made, and 0.1-ml samples of tissue suspension or blood
were plated on agar dishes containing 5% horse blood. Samples for
bacteriological examination of joints were obtained using sterilized
cotton sticks, after dissection of talocrural and radiocarpal joints,
and transferred to 5% horse blood agar. After incubation for 48 h
the colonies were counted and the results were expressed as the number
of CFU per milliliter blood or per whole organ.
Serological analyses. (i) Immunoglobulins.
Levels of IgG and
IgM in serum were measured by radial immunodiffusion (12).
Antiserum and Ig were purchased from Sigma Chemical Co. (St. Louis,
Mo.).
(ii) IL-6 assay.
Cell line B13.29, subclone B9, which is
dependent on IL-6 for its growth, was used for IL-6 determinations
(1, 10). B9 cells were harvested from tissue culture flasks,
seeded into microtiter plates (Nunc, Roskilde, Denmark) at 5,000 cells/well, and cultured in Iscove's medium supplemented with 5 × 10
5 M 2-mercaptoethanol, 5% fetal calf serum (Integro
B.V., Leuvenheim, The Netherlands), and 50 µg of gentamicin per ml
and serum samples were added. [3H]thymidine was added
after 68 h of culturing, and the cells were harvested 4 h
later. The samples were tested in twofold dilutions and compared with a
recombinant mouse IL-6 standard (Genzyme, Cambridge, Mass.)
(6). B9 cells were previously shown not to react with
several recombinant cytokines, including IL-1
, IL-1
, IL-2, IL-3,
IL-5, granulocyte-macrophage colony-stimulating factor, tumor necrosis
factor, and gamma interferon (IFN-
). There was only a weak
reactivity with IL-4 (10).
(iii) IFN-
assay.
Levels of IFN-
were measured by an
enzyme-linked immunosorbent assay using 2 µg of purified rat
anti-mouse IFN-
monoclonal antibody (PharMingen, San Diego, Calif.)
per ml in sodium bicarbonate (pH 9.6) for coating. All sera were
serially diluted in Tris-NaCl and incubated in wells. Biotinylated rat
anti-mouse IFN-
monoclonal antibody (2 µg/ml) (PharMingen) was
added to measure the level of IFN-
bound to the solid phase. This
procedure was followed by stepwise addition of streptavidin alkaline
phosphatase (Dako, Glostrup, Denmark). The enzyme substrate was then
added, and the absorbance was measured in a SpectraMax PLUS photometer
(Molecular Devices) at 405 nm. The samples were tested in twofold
dilutions and compared with a recombinant mouse IFN-
standard (Genzyme).
(iv) IL-4 and IL-10 assay.
Kits for detection of these
cytokines were purchased from R&D Systems. Detection limits in our
assays were 47 pg/ml and 2 pg/ml, respectively.
Statistical analysis.
The mortality rate and the frequency
of arthritis were analyzed using the
2 test with Yates'
correction. All the remaining parameters were analyzed by the
Mann-Whitney U test. All data are expressed as means ± standard errors
of the means unless otherwise indicated.
 |
RESULTS |
B lymphocytes do not affect the course of S. aureus
arthritis or sepsis.
The clinical outcome of arthritis varied
among the three experiments due to inoculation of different numbers of
bacteria. However, no statistically significant differences with
respect to arthritis between the µMT and the wild-type mice were
observed in any of the experiments. In the experiment where the mice
were inoculated with an optimal arthritogenic dose of bacteria (4 × 107/mouse), 70% of the µMT mice (n = 10) developed arthritis by day 7 whereas the corresponding rate
for their littermate controls (n = 11) was 81%. The
mice in the low-dose experiment (1 × 107/mouse) had a
lower frequency of arthritis: on day 7, 36% of the µMT mice
(n = 11) had developed arthritis and 27% of the
wild-type controls had done so. In the sepsis experiment, the mice were inoculated with a high dose of bacteria (1 × 109
CFU/mouse); 86% of the µMT mice (n = 11) and 60% of
the controls (n = 7) developed arthritis by day 4. Also, the severity of arthritis was similar between µMT and wild-type
controls in all three experiments (data not shown). The clinical
observations were confirmed by histopathological analysis of joints
(Table 1).
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Absence of B cells does not affect histopathological
progression of S. aureus arthritis in wild-type or
µMT micea
|
|
No deaths were recorded as a result of inoculation with the
arthritogenic and subarthritogenic doses of bacteria (1 × 10
7 and 4 × 10
7, respectively).
Inoculation of B-cell-deficient mice with a septic
dose (1 × 10
9) of
S. aureus resulted in a somewhat
increased mortality compared
to that of wild-type controls (45% [5 of
11] and 13% [1 of 7],
respectively). However, these data did not
reach statistical significance.
Furthermore, the general condition of
the mice as measured by
weight gain or loss showed no differences
between the groups (data
not
shown).
B cells do not influence the elimination of S. aureus
in vivo.
To assess the elimination of S. aureus during
infection, bacterial counts in blood were measured after 18 h and
3 days. In addition, bacterial counts in the kidneys, liver, and joints
were measured at the time of sacrifice. There were no significant
differences between the mice, irrespective of their B-cell status, in
any of the experiments (Fig. 1). The
shorter life span of the mice in the septic-dose experiment explains
the lower bacterial burden.

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 1.
B-cell deficiency does not influence bacterial clearance
in the kidneys. In the low-dose (1 × 107
bacteria/mouse) experiment, µMT (n = 11) and
wild-type (n = 11) mice were sacrificed on day 14; in
the moderate-dose (4 × 107 bacteria/mouse)
experiment, µMT (n = 11) and wild-type (n = 10) mice were sacrificed on day 11; and, finally, in the
septic-dose experiment (1 × 109 bacteria/mouse), the
µMT (n = 6) and wild-type (n = 6)
mice were sacrificed on day 7.
|
|
Decreased production of IFN-
in response to S. aureus infection in B-cell-deficient mice.
To further study
the cellular basis of responses to S. aureus, levels of
cytokines in serum were determined. As shown in Fig. 2, there was a striking reduction of
IFN-
levels in the µMT mice following infection with S. aureus. No differences in the levels of IL-4, IL-6, and IL-10 were
found (Table 2).

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 2.
Levels of IFN- in serum are significantly reduced in
the B10.Q (H-2q) µMT mice compared to the
wild-type controls. The levels were measured in the moderate-dose
(4 × 107 bacteria/mouse) experiment on days 2, 7, and
11.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Levels of cytokines in serum following S. aureus infection in B-cell-deficient (µMT) and wild-type
congeneic mice
|
|
 |
DISCUSSION |
This study demonstrates that a complete absence of functional B
cells in the µMT mice affects neither susceptibility to nor outcome
of S. aureus-induced septic arthritis and sepsis-related mortality. In addition, B cells do not influence the rate of in vivo
elimination of staphylococci.
We have previously shown that mice with X-linked immunodeficiency (xid
mice) are less susceptible to septic arthritis than are their congeneic
controls, probably because of a changed cytokine profile, characterized
by decreased production of IL-1
and IL-6 and increased synthesis of
IFN-
combined with poor antibody responses (21). The xid
mice have relatively few functional B cells of the B2 subset and have
no B1 cells. Since the B1 subset of B cells is an important source of
autoantibody production, it may be hypothesized that deletion of this
population might have had a beneficial impact on the outcome of
S. aureus arthritis, a disease characterized by the
production of high levels of rheumatoid factors, collagen II
antibodies, and anti-DNA antibodies (7). In contrast, the B2
subset of B cells has the capacity to produce antibodies to extrinsic
molecules, e.g., bacterial antigens. These antibodies might, at least
under certain circumstances, be important in the defense against
S. aureus sepsis and arthritis. Indeed, we have recently
shown that antibodies specific to staphylococcal collagen adhesin
(15) and enterotoxins (16) have a protective
capacity. Thus, we hypothesize that the opposing properties of B1
versus B2 cell products might have neutralized each other's effect.
It has recently been shown that B cells are crucial to the progression
of collagen type II-induced arthritis (19). It was suggested
that B cells were important antigen-presenting cells and that some of
them (i.e., those specific for collagen type II) were important for
antigen uptake and thereby enhanced macrophage activity. The type of
challenge used in different studies of B-cell-deficient mice is vital
to the experimental outcome. In the present study, rather than a single
antigen, live bacteria encompassing a multitude of antigens, mitogens,
and superantigen were employed.
Is the ability of the B cells to present antigens important to the
acquisition of an efficient immune response to the infectious agent? In
this study, this does not seem to be the case. Previously it has been
shown that B cells are not mandatory as antigen-presenting cells for
T-cell priming, at least with respect to soluble protein antigens
(9, 17, 20). Interestingly, a recent study indicated that
intraperitoneal inoculation of µMT mice with Listeria
monocytogenes did not affect the clinical outcome of the disease
but led to significantly lower production of IFN-
(13).
This outcome is similar to our findings with S. aureus, an
extracellularly growing bacterium. The mechanism responsible for the
decrease of IFN
production is unclear but may be dependent on the
expression of costimulatory molecules, such as B7 and CD40, on
antigen-presenting cells. There are several studies which show the
importance of CD40/CD40L costimulation for regulation of Th1 responses.
Thus CD40L-deficient (
/
) mice fail to produce IFN-
during the
induction phase of 2,6-trinitrobenzene sulfonic acid (TNBS)-induced
colitis (18). In addition, stimulation with a CD40L agonist
enhanced IFN-
production by human peripheral blood mononuclear cells
(14).
Our findings showing deficient production of IFN-
are confirmed by
the results of Matsazuki et al. (13) and may be explained by
a diminished number of major histocompatibility complex class II
molecules, CD40, B7-1, and B7-2 molecules, and thereby an impaired T-cell priming. In addition, the decreased number of class
II-expressing cells due to lack of the B-cell population might have
affected the superantigenic responses, since the IFN-
is a cytokine
whose secretion is readily triggered by TSST-1 (22).
Finally, it has recently been shown that clonal expansion of
superantigen-reactive T cells is diminished in µMT mice compared to
intact controls (20).
This study demonstrates that the clinical and histopathological outcome
of septic arthritis and sepsis-related mortality in response to
intravenously inoculated S. aureus is identical in B-cell-deficient mice and their congeneic controls. Interestingly, significantly decreased IFN-
levels and absence of Ig production in
the µMT mice did not affect the in vivo clearance of bacteria.
 |
ACKNOWLEDGMENTS |
We thank Lena Svensson and Margareta Verdrengh for excellent
technical assistance.
This work was supported by the Göteborg Medical Society, the
Swedish Association against Rheumatism, the King Gustaf V. Foundation, the Swedish Medical Research Council, Inflammation Network, Infection and Vaccinology Network, the Nanna Swartz Foundation, the AME Wolff
Foundation, and the University of Göteborg.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Rheumatology, Göteborgs Universitet, Guldhedsgatan 10A, S-413 46 Göteborg, Sweden. Phone: 46 31 342 29 62. Fax: 46 31 82 39 25. E-mail: inger.gjertsson{at}immuno.gu.se.
Editor:
E. I. Tuomanen
 |
REFERENCES |
| 1.
|
Aarden, L. A.,
E. R. De Groot,
O. L. Schaap, and P. M. Lansdorp.
1987.
Production of hybridoma growth factor by human monocytes.
Eur. J. Immunol.
17:1411-1416[Medline].
|
| 2.
|
Abdelnour, A.,
S. Arvidson,
T. Bremell,
C. Ryden, and A. Tarkowski.
1993.
The accessory gene regulator (agr) controls Staphylococcus aureus virulence in a murine arthritis model.
Infect Immun.
61:3879-3885[Abstract/Free Full Text].
|
| 3.
|
Abdelnour, A.,
T. Bremell,
R. Holmdahl, and A. Tarkowski.
1994.
Clonal expansion of T lymphocytes causes arthritis and mortality in mice infected with toxic shock syndrome toxin-1-producing staphylococci.
Eur. J. Immunol.
24:1161-1166[Medline].
|
| 4.
|
Abdelnour, A.,
T. Bremell,
R. Holmdahl, and A. Tarkowski.
1994.
Role of T lymphocytes in experimental Staphylococcus aureus arthritis.
Scand. J. Immunol.
39:403-408[CrossRef][Medline].
|
| 5.
|
Abdelnour, A.,
T. Bremell, and A. Tarkowski.
1994.
Toxic shock syndrome toxin 1 contributes to the arthritogenicity of Staphylococcus aureus.
J. Infect. Dis.
170:94-99[Medline].
|
| 6.
|
Brakenhoff, J. P.,
E. R. de Groot,
R. F. Evers,
H. Pannekoek, and L. A. Aarden.
1987.
Molecular cloning and expression of hybridoma growth factor in Escherichia coli.
J. Immunol.
139:4116-4121[Abstract]. (Erratum, 140:4413, 1988.)
|
| 7.
|
Bremell, T.,
A. Abdelnour, and A. Tarkowski.
1992.
Histopathological and serological progression of experimental Staphylococcus aureus arthritis.
Infect. Immun.
60:2976-2985[Abstract/Free Full Text].
|
| 8.
|
Bremell, T.,
S. Lange,
A. Yacoub,
C. Ryden, and A. Tarkowski.
1991.
Experimental Staphylococcus aureus arthritis in mice.
Infect. Immun.
59:2615-2623[Abstract/Free Full Text].
|
| 9.
|
Epstein, M. M.,
F. Di Rosa,
D. Jankovic,
A. Sher, and P. Matzinger.
1995.
Successful T cell priming in B cell-deficient mice.
J. Exp. Med.
182:915-922[Abstract/Free Full Text].
|
| 10.
|
Helle, M.,
L. Boeije, and L. A. Aarden.
1988.
Functional discrimination between interleukin 6 and interleukin 1.
Eur. J. Immunol.
18:1535-1540[Medline].
|
| 11.
|
Kitamura, D.,
J. Roes,
R. Kuhn, and K. Rajewsky.
1991.
A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene.
Nature
350:423-426[CrossRef][Medline].
|
| 12.
|
Mancini, G.,
A. O. Carbonara, and J. F. Heremans.
1965.
Immunochemical quantitation of antigens by single radial immunodiffusion.
Immunochemistry
2:235-254[CrossRef][Medline].
|
| 13.
|
Matsuzaki, G.,
H. M. Vordermeier,
A. Hashimoto,
K. Nomoto, and J. Ivanyi.
1999.
The role of B cells in the establishment of T cell response in mice infected with an intracellular bacteria, Listeria monocytogenes.
Cell. Immunol.
194:178-185[CrossRef][Medline].
|
| 14.
|
McDyer, J. F.,
T. J. Goletz,
E. Thomas,
C. H. June, and R. A. Seder.
1998.
CD40 ligand/CD40 stimulation regulates the production of IFN-gamma from human peripheral blood mononuclear cells in an IL-12- and/or CD28-dependent manner.
J. Immunol.
160:1701-1707[Abstract/Free Full Text].
|
| 15.
|
Nilsson, I. M.,
J. M. Patti,
T. Bremell,
M. Hook, and A. Tarkowski.
1998.
Vaccination with a recombinant fragment of collagen adhesin provides protection against Staphylococcus aureus-mediated septic death.
J. Clin. Investig.
101:2640-2649[Medline].
|
| 16.
|
Nilsson, I. M.,
M. Verdrengh,
R. G. Ulrich,
S. Bavari, and A. Tarkowski.
1999.
Protection against Staphylococcus aureus sepsis by vaccination with recombinant staphylococcal enterotoxin A devoid of superantigenicity.
J. Infect. Dis.
180:1370-1373[CrossRef][Medline].
|
| 17.
|
Phillips, J. A.,
C. G. Romball,
M. V. Hobbs,
D. N. Ernst,
L. Shultz, and W. O. Weigle.
1996.
CD4+ T cell activation and tolerance induction in B cell knockout mice.
J. Exp. Med.
183:1339-1344[Abstract/Free Full Text].
|
| 18.
|
Stuber, E.,
W. Strober, and M. Neurath.
1996.
Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion.
J. Exp. Med.
183:693-698[Abstract/Free Full Text].
|
| 19.
|
Svensson, L.,
J. Jirholt,
R. Holmdahl, and L. Jansson.
1998.
B cell-deficient mice do not develop type II collagen-induced arthritis (CIA).
Clin. Exp. Immunol.
111:521-526[CrossRef][Medline].
|
| 20.
|
Vella, A. T.,
M. T. Scherer,
L. Schultz,
J. W. Kappler, and P. Marrack.
1996.
B cells are not essential for peripheral T-cell tolerance.
Proc. Natl. Acad. Sci. USA
93:951-955[Abstract/Free Full Text].
|
| 21.
|
Zhao, Y. X.,
A. Abdelnour,
R. Holmdahl, and A. Tarkowski.
1995.
Mice with the xid B cell defect are less susceptible to developing Staphylococcus aureus-induced arthritis.
J. Immunol.
155:2067-2076[Abstract].
|
| 22.
|
Zhao, Y. X.,
A. Abdelnour,
A. Ljungdahl,
T. Olsson, and A. Tarkowski.
1995.
Patterns of interferon-gamma mRNA expression in toxic shock syndrome toxin-1 expanded V beta 11+ T lymphocytes.
Cell. Immunol.
161:28-33[CrossRef][Medline].
|
Infection and Immunity, May 2000, p. 2431-2434, Vol. 68, No. 5
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.